January 16, 2020January 14, 2020
I’m Channeling My Grief About ALS into Action and Advocacy
Columns, Joyful Sorrow - a Column by Kristin Neva
The grief that accompanies ALS is multifaceted. I grieve my husband’s loss of function and the loss of our ... Read more
January 16, 2020
Neos Completes Dosing in Phase 1 Trial of Anti-Drooling Treatment NT0502 in Healthy Volunteers
News
Dosing of healthy volunteers has been completed in a Phase 1 clinical trial evaluating Neos Therapeutics‘ experimental therapy NT0502 ... Read more
January 15, 2020January 15, 2020
Alexion to Initiate Phase 3 Trial of Ultomiris for Familiar, Sporadic ALS Patients
News
In the coming months, Alexion Pharmaceuticals will launch a pivotal Phase 3 clinical trial to test its complement system inhibitor ... Read more
January 14, 2020January 10, 2020
A New Paradigm for the Future of ALS
Columns, Living Well with ALS - a column by Dagmar Munn
The new year arrived bearing good and bad news. The good news is that 2020 marks my 10th year ... Read more
January 14, 2020January 14, 2020
ALS Research Ambassador Collaboration Enabled More Patient-centered Design of REFINE-ALS Trial
News
Including ALS Research Ambassadors — a group of amyotrophic lateral sclerosis (ALS) patients and their caregivers — in discussions about future ... Read more
January 13, 2020January 13, 2020
AstroRx Increases Ability to Perform Daily Functions in ALS Patients, Trial Results Show
News
Amyotrophic lateral sclerosis (ALS) patients receiving the lowest dose of Kadimastem’s cell therapy candidate, AstroRx, experienced a significant reduction ... Read more
January 10, 2020January 10, 2020
Kadimastem Finishes Treating Second Group of ALS Patients with AstroRx in Phase 1/2a Trial
News
Kadimastem has finished treating its second group of participants in a Phase 1/2a clinical trial testing the safety and ... Read more
January 9, 2020January 8, 2020
Learning the Rules for the Medicare Guessing Game
Columns, Joyful Sorrow - a Column by Kristin Neva
Like many families, we played games over the holidays. Because my husband, Todd, is completely paralyzed due to ALS, ... Read more
January 9, 2020January 15, 2020
Mitochondrial ‘Suicide’ May Signal Start of Neurodegeneration in ALS, Mouse Study Suggests
News
A newly discovered self-destructive mechanism in mitochondria, the cells’ powerhouses, may be one of the first deficits leading to ... Read more
January 8, 2020January 8, 2020
Insurance Data May Predict ALS, Research Shows
News
A machine-learning model based on insurance information from amyotrophic lateral sclerosis (ALS) patients may be able to speed diagnosis ... Read more
January 7, 2020January 3, 2020
Join Our Virtual Friendly Neighborhood, the ALS News Today Forums
Columns, Living Well with ALS - a column by Dagmar Munn
Last year, while serving as a moderator for the ALS News Today Forums, I added more than 355 ... Read more
January 7, 2020January 7, 2020
END ALS Association Founder Lights Up Room With Holiday Spirit to Raise Disease Awareness
News
The founder of the END ALS Association, Masahiro “Hiro” Fujita, can no longer move and can barely communicate because ... Read more

January 16, 2020January 14, 2020

I’m Channeling My Grief About ALS into Action and Advocacy

Columns, Joyful Sorrow - a Column by Kristin Neva

The grief that accompanies ALS is multifaceted. I grieve my husband’s loss of function and the loss of our dreams. Just when we find a new normal, there is ... Read more

January 16, 2020

Neos Completes Dosing in Phase 1 Trial of Anti-Drooling Treatment NT0502 in Healthy Volunteers

News

Dosing of healthy volunteers has been completed in a Phase 1 clinical trial evaluating Neos Therapeutics‘ experimental therapy NT0502 for chronic sialorrhea (excessive drooling), a common problem in people with amyotrophic ... Read more

January 15, 2020January 15, 2020

Alexion to Initiate Phase 3 Trial of Ultomiris for Familiar, Sporadic ALS Patients

News

In the coming months, Alexion Pharmaceuticals will launch a pivotal Phase 3 clinical trial to test its complement system inhibitor Ultomiris (ravulizumab) in people with amyotrophic lateral sclerosis (ALS) whose ... Read more

January 14, 2020January 10, 2020

A New Paradigm for the Future of ALS

Columns, Living Well with ALS - a column by Dagmar Munn

The new year arrived bearing good and bad news. The good news is that 2020 marks my 10th year of living with ALS and I’m still here! The bad ... Read more

January 14, 2020January 14, 2020

ALS Research Ambassador Collaboration Enabled More Patient-centered Design of REFINE-ALS Trial

News

Including ALS Research Ambassadors — a group of amyotrophic lateral sclerosis (ALS) patients and their caregivers — in discussions about future clinical trial planning and design facilitates changes in study protocol ... Read more

January 13, 2020January 13, 2020

AstroRx Increases Ability to Perform Daily Functions in ALS Patients, Trial Results Show

News

Amyotrophic lateral sclerosis (ALS) patients receiving the lowest dose of Kadimastem’s cell therapy candidate, AstroRx, experienced a significant reduction in disease progression in the three or four months after treatment, ... Read more

January 10, 2020January 10, 2020

Kadimastem Finishes Treating Second Group of ALS Patients with AstroRx in Phase 1/2a Trial

News

Kadimastem has finished treating its second group of participants in a Phase 1/2a clinical trial testing the safety and preliminary efficacy of AstroRx, an investigational stem cell therapy for amyotrophic ... Read more

January 9, 2020January 8, 2020

Learning the Rules for the Medicare Guessing Game

Columns, Joyful Sorrow - a Column by Kristin Neva

Like many families, we played games over the holidays. Because my husband, Todd, is completely paralyzed due to ALS, we chose games in which he could participate. Apples to ... Read more

January 9, 2020January 15, 2020

Mitochondrial ‘Suicide’ May Signal Start of Neurodegeneration in ALS, Mouse Study Suggests

News

A newly discovered self-destructive mechanism in mitochondria, the cells’ powerhouses, may be one of the first deficits leading to motor neuron degeneration associated with toxic TDP-43 clumps — a hallmark ... Read more

January 8, 2020January 8, 2020

Insurance Data May Predict ALS, Research Shows

News

A machine-learning model based on insurance information from amyotrophic lateral sclerosis (ALS) patients may be able to speed diagnosis of the disease in others, research suggests. The findings were ... Read more

January 7, 2020January 3, 2020

Join Our Virtual Friendly Neighborhood, the ALS News Today Forums

Columns, Living Well with ALS - a column by Dagmar Munn

Last year, while serving as a moderator for the ALS News Today Forums, I added more than 355 people to my circle of ALS friends. And in the short ... Read more

January 7, 2020January 7, 2020

END ALS Association Founder Lights Up Room With Holiday Spirit to Raise Disease Awareness

News

The founder of the END ALS Association, Masahiro “Hiro” Fujita, can no longer move and can barely communicate because of amyotrophic lateral sclerosis (ALS). To help him enjoy the holidays ... Read more